GAMMA Investing LLC Has $128,000 Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GAMMA Investing LLC boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 29.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,316 shares of the medical equipment provider’s stock after buying an additional 298 shares during the quarter. GAMMA Investing LLC’s holdings in Lantheus were worth $128,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Pictet Asset Management Holding SA boosted its stake in shares of Lantheus by 12.1% during the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider’s stock worth $921,000 after acquiring an additional 1,113 shares during the period. Cetera Investment Advisers boosted its stake in shares of Lantheus by 22.7% during the 4th quarter. Cetera Investment Advisers now owns 23,358 shares of the medical equipment provider’s stock worth $2,090,000 after acquiring an additional 4,320 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Lantheus by 4.8% during the 1st quarter. Harbor Capital Advisors Inc. now owns 152,317 shares of the medical equipment provider’s stock worth $14,866,000 after acquiring an additional 6,938 shares during the period. Norges Bank bought a new position in shares of Lantheus during the 4th quarter worth approximately $26,189,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Lantheus by 108.3% during the 4th quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider’s stock worth $203,000 after acquiring an additional 1,182 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. B. Riley reduced their target price on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research note on Monday, June 23rd. Truist Financial reduced their target price on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $130.50.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $79.21 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The stock’s fifty day moving average price is $82.57 and its two-hundred day moving average price is $90.24. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.12.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the company earned $1.69 earnings per share. The business’s quarterly revenue was up .8% compared to the same quarter last year. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the company’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company’s stock, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.